CAS: 674289-55-5; 3A-Hydroxy-6-Methyl-1-Phenyl-1,2,3,3A-Tetrahydro-4H-Pyrrolo[2,3-B]Quinolin-4-One
该化合物是一种选择性的细胞透视抑制器,它专门针对非肌肉肌膜肌内膜内膜内膜二型ATPase循环. 它表现出很高的能量,IC50 的浓度为 0.5-5 微米,并被广泛用于研究细胞骨骼动态,细胞机能和合同工艺. Blebistain 的主要优势是其可逆抑制机制,它允许实验环境中精确的时间控制.它与其他近氧抑制剂相比,它表现出最低的非目标效果,使其成为研究机械学和细胞机械的宝贵工具. 此外,它在生理条件下的稳定可以确保活细胞成像和功能实验的可靠性表现.
- 英文名称3A-Hydroxy-6-Methyl-1-Phenyl-1,2,3,3A-Tetrahydro-4H-Pyrrolo[2,3-B]Quinolin-4-One
- 中文名称(+/-)-布雷比司他汀
- IUPAC名称3a-hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one
- 其它别名(R)-(+)-BLEBBISTATIN; (3AS)-(-)-1,2,3,3A-TETRAHYDRO-3A-HYDROXY-6-METHYL-1-PHENYL-4H-PYRROLO[2,3-B]QUINOLIN-4-ONE; (+/-)-1-PHENYL-1,2,3,4-TETRAHYDRO-4-HYDROXYPYRROLO[2,3-B]-7-METHYLQUINOLIN-4-ONE; (+/-)-1,2,3,3A-TETRAHYDRO-3A-HYDROXY-6-METHYL-1-PHENYL-4H-PYRROLO[2,3-B]QUINOLIN-4-ONE; (+/-)-1-Phenyl-1,2,3,4-tetrahydro-4-hydroxypyrrolo[2,3-β]-7-methylquinolin-4-one; 1,2,3,3a-Tetrahydro-3a-hydroxy-6-methyl-1-phenyl-4H-pyrrolo[2,3-β]quinolin-4-one; (3aR)-1,2,3,3a-Tetrahydro-3a-hydroxy-6-methyl-1-phenyl-4H-pyrrolo[2,3-β]quinolin-4-one; (3aS)-1,2,3,3a-Tetrahydro-3a-hydroxy-6-methyl-1-phenyl-4H-pyrrolo[2,3-β]quinolin-4-one
- CAS编号674289-55-5
- MFCD编号:MFCD04113775
- FDA UNII编号:20WC4J7CQ6
- 分子式:C18H16N2O2分子量:292.34
- 产品CID: 1656930
- 同类组份化合物CAS856925-71-8 (S-isomer)1177356-70-5 (R-isomer)674289-55-5 (racemic)
- 产品分类生物 → 生化试剂盒
物理性质
- 熔点210-212 °C
- 沸点507.3±60.0 °C at 760 mmHg
- 闪点260.6±32.9 °C
- 密度1.3±0.1 g/cm3
- pKa:11.15±0.20(预测)
- PSA:52.9
- LogP:1.62
- 折射率1.681
- 蒸汽压0.0±1.4 mmHg at 25°C
- 溶解性Chloroform (Slightly), Dichloromethane, DMSO, Ethyl Acetate, Methanol
- 外观形态黄色亮黄色固体
- 储存条件−20°C
- 产品应用该化合物用作促进角膜内皮细胞的方向迁移,加速伤口愈合,同时更好地保护细胞交叉的完整性和屏障功能;它阻塞了细胞内膜二独立细胞过程,迅速和可逆地抑制细胞抽搐,扰乱了脊椎细胞中定向细胞迁移和细胞基尼,并抑制了50-100 微米浓度的抽血和细胞金素.
MSDS等安全信息
上下游产品
Methyl 5-Methyl-2-(1-Phenylpyrrolidin-2-Ylideneamino)Benzoate合成工艺路线路线简述
📜1-苯基-2-吡咯烷酮置于氧气,Lithium Hexamethyldisilazane,三氯氧磷体系中,用 四氢呋喃,二氯甲烷 作为反应溶剂,化学反应 25.0H,反应生成 (卤)-Blebbistatin
参考文献:小分子工具 (-)-Blebbistatin 的绝对立体化学分配和荧光调谐
标题:小分子工具 (-)-Blebbistatin 的绝对立体化学分配和荧光调谐
摘要:(-)-Blebbistatin (1) 是最近发现的非肌肉肌球蛋白 Ii Atpase 活性的小分子抑制剂,已从 5-甲基邻氨基苯甲酸甲酯 (6) 分三步制备.这种灵活的合成路线也已被用于制备含硝基的类似物 12,该类似物在显微镜照明下具有改进的荧光特性和改进的稳定性.合成 1 及其类似物的关键步骤是使用 Davis Oxaziridine 方法对喹诺酮中间体 3 进行不对称羟基化.通过对含有类似物 11 的重原子(溴)进行 X 射线晶体结构分析,(-)-Blebbistatin (1) 的绝对立体化学显示为 S,随后将其还原并显示与 1 相同.
DOI:10.1002/ejoc.200500103
海关参考信息
- 2902600000-乙苯
2905122000-异丙醇
2905143000-叔丁醇
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-8697385-B1
优先权日:2009-10-06
标 题 :Protein controlling synthesis of collagen and associated methods
发明人：STEFANOVIC BRANKO
权利人:UNIV FLORIDA STATE RES FOUND; UNIV FLORIDA STATE RES FOUND
摘要:A method of screening an agent for ability to interfere with collagen synthesis includes the steps of reacting a polypeptide having an amino acid sequence comprising SEQ ID NO: 1 with collagen mRNAs in the presence of the agent and detecting if the agent has interfered with binding of the polypeptide to the mRNAs. Another method includes the steps of reacting the polypeptide with nonmuscle myosin filaments in the presence of the agent and detecting if the agent has interfered with binding of the polypeptide to the nonmuscle myosin filaments.
专利号:US-2019328845-A1
优先权日:2011-09-30
标 题 :In vivo synthesis of elastic fiber
专利号:KR-102527367-B1
优先权日:2011-09-30
标 题 :In vivo synthesis of elastic fiber
专利号:CA-2850384-A1
优先权日:2011-09-30
标 题:In vivo synthesis of elastic fiber
专利号:TR-201905884-T4
优先权日:2011-09-30
标 题:In vivo synthesis of elastic fiber.
专利号:KR-101969104-B1
优先权日:2011-09-30
标题:In vivo synthesis of elastic fiber
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Boberg L, Rahman A, Poljakovic M, Arner A. Protein kinase C activation of a blebbistatin sensitive contractile component in the wall of hypertrophying mouse urinary bladder. Neurourol Urodyn. 2015 Feb;34(2):196-202. doi: 10.1002/nau.22531. Epub 2013 Nov 26. doi: 10.1007/s11626-014-9836-0. Epub 2014 Nov 18. doi: 10.1016/j.bpj.2014.07.075.
4: Doller A, Badawi A, Schmid T, Brauss T, Pleli T, zu Heringdorf DM, Piiper A, Pfeilschifter J, Eberhardt W. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp Cell Res. 2015 Jan 1;330(1):66-80. doi: 10.1016/j.yexcr.2014.09.010. Epub 2014 Sep 21. doi: 10.1007/s00894-012-1750-3. Epub 2013 Jan 13. doi: 10.1113/expphysiol.2012.069369. Epub 2013 Jan 4.
7: Yumoto M, Watanabe M. Blebbistatin, a myosin II inhibitor, suppresses Ca(2+)-induced and "sensitized"-contraction of skinned tracheal muscles from guinea pig. J Smooth Muscle Res. 2013;49:89-98. doi: 10.1007/s00424-012-1147-2. Epub 2012 Sep 19.
合成参考文献
参考文献:10.1152/ajpcell.00043.2011
摘要:Lang E, Qadri SM, Zelenak C, Gu S, Rotte A, Draeger A, Lang F. Inhibition of suicidal erythrocyte death by blebbistatin. American Journal of Physiology-Cell Physiology. 2011 Aug;301(2):C490–8. doi: 10.1152/ajpcell.00043.2011.
参考文献:10.1016/j.yjmcc.2012.12.011
摘要:Miura M, Murai N, Hattori T, Nagano T, Stuyvers BD, Shindoh C. Role of reactive oxygen species and Ca2+ dissociation from the myofilaments in determination of Ca2+ wave propagation in rat cardiac muscle. Journal of Molecular and Cellular Cardiology. 2013 Mar;56():97–105. doi: 10.1016/j.yjmcc.2012.12.011.
参考文献:10.1021/acs.analchem.9b01092
摘要:Simeonov S, Schäffer TE. Ultrafast Imaging of Cardiomyocyte Contractions by Combining Scanning Ion Conductance Microscopy with a Microelectrode Array. Anal Chem. 2019 Aug 06;91(15):9648–55. doi: 10.1021/acs.analchem.9b01092.
参考文献:10.1016/j.bbrc.2003.12.031
摘要:Duxbury MS, Ashley SW, Whang EE. Inhibition of pancreatic adenocarcinoma cellular invasiveness by blebbistatin: a novel myosin II inhibitor. Biochemical and Biophysical Research Communications. 2004 Jan;313(4):992–7. doi: 10.1016/j.bbrc.2003.12.031.
参考文献:10.1074/jbc.m402292200
摘要:Yoshizaki H, Ohba Y, Parrini M, Dulyaninova NG, Bresnick AR, Mochizuki N, Matsuda M. Cell Type-specific Regulation of RhoA Activity during Cytokinesis. Journal of Biological Chemistry. 2004 Oct;279(43):44756–62. doi: 10.1074/jbc.m402292200.
📝 需求与反馈
尽可能描述清楚需求与问题信息
